CUMBERLAND, R.I.--(BUSINESS WIRE)--Neurotech Pharmaceuticals, a biotechnology company developing transformational, sight-saving therapeutics for the treatment of chronic eye diseases, announced today ...

CUMBERLAND, R.I.--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced that the U.S. Food and ...

Neurotech Pharmaceuticals, Inc. (the "Company") today provided an update on its ongoing transition to a commercial--stage company following the first anniversary of the FDA's approval of ENCELTO(TM) ...

Please provide your email address to receive an email when new articles are posted on . Neurotech submitted a biologics license application for its macular telangiectasia therapy, NT-501, to the FDA ...

CUMBERLAND, R.I., June 02, 2026--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc. (the "Company") announces the launch of YouTube channel - Uncovering MacTel, a new disease education resource that ...

Protein therapies for the eye must be dosed as frequent injections. Gene therapy offers one-time treatment, but must also be administered by injection. Neurotech Pharmaceuticals’ gene therapy comes in ...

A pair of phase 3 trials of Neurotech Pharmaceuticals’ encapsulated cell therapy implant have met their primary endpoints, positioning the biotech to talk to the FDA about bringing the treatment for a ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Neurotech is developing novel ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Neurotech Pharmaceuticals Inc. has raised $35 million in a ...

Neurotech Pharmaceuticals, Inc. (the “Company”) announces the launch of YouTube channel - Uncovering MacTel, a new disease education resource that delivers accessible, patient-centered information for ...